We're working on a new version of PRX. Want a sneak peek?

Piece image

Solving The Head & Neck Cancer Puzzle with Cel-Sci's Geert Kersten

From: Eric Michaels
Series: eHealth Radio Report
Length: 15:58

Embed_button
CEL-SCI's story is one of vision, persistence, and survival in the face of overwhelming odds. CEO Geert Kersten has been involved in the pioneering field of cancer immunotherapy for almost two decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry.

Ehealthradiosquareicon_small CEL-SCI's story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, lack of funding, and a lengthy clinical trial process associated with the development of its investigational therapy for advanced primary head and neck cancer, CEL-SCI is finally at the end game with an investigational immunotherapy, Multikine® currently being tested in a global Phase III trial.

The firm has taken a rather unconventional path with the ground-breaking treatment, which has gotten the attention of both Wall Street Investors and The National Institute of Health. The drug has been highlighted by several publications recently as one of the most promising new cancer treatments in development and under review by the FDA.

Piece Description

CEL-SCI's story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, lack of funding, and a lengthy clinical trial process associated with the development of its investigational therapy for advanced primary head and neck cancer, CEL-SCI is finally at the end game with an investigational immunotherapy, Multikine® currently being tested in a global Phase III trial.

The firm has taken a rather unconventional path with the ground-breaking treatment, which has gotten the attention of both Wall Street Investors and The National Institute of Health. The drug has been highlighted by several publications recently as one of the most promising new cancer treatments in development and under review by the FDA.

Comments

The producer has turned off comments on this piece.

Broadcast History

The eHealth Radio Report has been on the air since 2010. They are broadcasting on a growing number of public radio and HD Radio stations

Intro and Outro

INTRO:

Host, Eric Michaels focuses on the leaders and innovators in the healthcare field in this edition of the eHealth Radio Report.

OUTRO:

Related Website

http://cel-sci.com/